Seeking Alpha

Haemonetics (HAE) Q2 results came in mixed late yesterday, beating on a per share basis, but...

Haemonetics (HAE) Q2 results came in mixed late yesterday, beating on a per share basis, but coming up slight shy on the revenue side. Total revenue was up nearly 22% Y/Y however, on continued strength in across its entire product portfolio. Barrington thinks the quarter was strong believes that its integration of PALL is proceeding better than expected. The firm raised its target on the stock to $88 from $79 yesterday and reiterates an Outperform on the stock.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|